SRX246: Clinical Trials

7 trials of SRX246, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 not yet recruiting, 1 terminated, 1 unknown. 4 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Completed 3, Unknown 1
Phase 24Completed 2, Not yet recruiting 1, Terminated 1

Follow SRX246: new trials by email Literature Review of SRX246 trials Research Report on SRX246

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome
SRX246, Placebo - Aggressive Behavior in Fragile X Syndome
Phase 2Not yet recruitingAzevan Pharmaceuticals802026-03-012026-01-09
Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans
SRX246, Placebo - Fear, Anxiety
Phase 1UnknownAzevan Pharmaceuticals362017-02-032019-06-10
Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD
SRX246, Placebo - PTSD
Phase 2TerminatedAzevan Pharmaceuticals332016-12-012021-11-01
Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
SRX246, Placebo - Irritable Mood, Huntington's Disease
Phase 2CompletedAzevan Pharmaceuticals1062016-05-102023-07-20
Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder
SRX246, Placebo - Intermittent Explosive Disorder
Phase 1 / Phase 2CompletedAzevan Pharmaceuticals972014-05-012023-07-21
Multiple Dose Safety Study of SRX246 Capsules in Healthy Volunteers
SRX246 - Healthy
Phase 1CompletedAzevan Pharmaceuticals242010-03-012010-07-20
Study of SRX246 Capsules in Healthy Adult Volunteers
SRX246, Placebo - Healthy
Phase 1CompletedAzevan Pharmaceuticals492009-05-012010-03-17

Conditions studied

Aggression (2)  ·  Anxiety Disorders (1)  ·  Disruptive, Impulse Control, and Conduct Disorders (1)  ·  Fragile X Syndrome (1)  ·  Huntington Disease (1)  ·  Psychomotor Agitation (1)  ·  Self-Injurious Behavior (1)  ·  Stress Disorders, Post-Traumatic (1)

Sponsors

Azevan Pharmaceuticals (7)

Countries

United States (7)

Top investigators

Benno G Roesch, MD (1)  ·  Stephan A Bart, MD (1)

NIH funding

U44NS090616 (1)